This form of prostate cancer often continues AR signaling that is not reliant on androgen ligands (i.e., androgen independent) by way of multiple mechanisms, including mutations in the receptor or copy-number variations, and is typically treated with androgen-receptor inhibitors (ARIs) [10,11,12,13]. This evidence concerns the gene AR and prostate carcinoma.